Cognitive / Neuro · Research guide

Semax peptide: Cognitive / Neuro research guide

Semax is listed in our catalogue under “Cognitive / Neuro.” In scientific publications it is discussed in technical language; this page translates the general themes into everyday wording while staying faithful to research-only framing.

Plain-language snapshot

One-paragraph overview from our research datasheet—still scientific, but faster to read than the full mechanism list below.

What shows up in scientific writing (general background)

Many readers want context before diving into pathways. The list below summarises what researchers and reviewers discuss—cells, animals, and (for some drug-class molecules) formal clinical trials. It is not a promise of results for any individual.

Typical study contexts & reported directions

• Stress, sleep, and neuronal signalling in rodents; peptide tools for probing pathways, not treating human cognition.
• Some compounds appear in small exploratory human studies elsewhere in the literature—still distinct from DIY use.
• Peer-reviewed preclinical work sometimes describes experiments that track whether rapidly upregulates BDNF and TrkB receptor expression in hippocampal neurons
• Peer-reviewed preclinical work sometimes describes experiments that track whether activates serotonergic neurotransmission—increases striatal 5-HIAA to 180% within 1–4 hours post-administration
• Peer-reviewed preclinical work sometimes describes experiments that track whether modulates dopaminergic signaling with increased DA metabolite turnover in the striatum
• Peer-reviewed preclinical work sometimes describes experiments that track whether competitively antagonizes α-MSH at MC4 and MC5 melanocortin receptors

Why Cognitive / Neuro research discusses this compound

Cognitive-related peptides are explored for stress-response pathways, neuronal signalling, and behaviour in animal models -not as treatments for human brain conditions.

Themes from preclinical literature (technical)

Below are mechanistic bullet points as they appear in our product reference material -useful for researchers comparing pathways. They are not simplified health claims.

• Rapidly upregulates BDNF and TrkB receptor expression in hippocampal neurons
• Activates serotonergic neurotransmission—increases striatal 5-HIAA to 180% within 1–4 hours post-administration
• Modulates dopaminergic signaling with increased DA metabolite turnover in the striatum
• Competitively antagonizes α-MSH at MC4 and MC5 melanocortin receptors
• Inhibits enkephalin-degrading enzymes (IC₅₀ = 10 μM) to potentiate endogenous opioid signaling
• Enhances operative memory, attention, and hypoxia resistance for 20–24 hours after intranasal dosing

Typical handling notes (from our datasheet)

Storage: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. ~5% degradation per year refrigerated. - see our storage guide for best practices on temperature, light, and shelf life.

Typical research dosing discussion (literature-style): 200–600 μg intranasal; 100–300 μg subcutaneous · Once daily intranasal (0.1% solution, 2–3 drops per nostril) · Plasma half-life 3–5 minutes, but functional biological duration extends to 20–24 hours due to downstream BDNF/TrkB signaling cascades. Intranasal administration delivers 0.093% of total dose to rat brain within 2 minutes, of which 80% is intact Semax. Pro-Gly-Pro tripeptide is the primary metabolite. Poor oral bioavailability necessitates intranasal or parenteral routes. Russian clinical doses: 0.015–0.050 mg/kg intranasally.

For preparation, follow the step-by-step reconstitution guide and use the reconstitution calculator to confirm draw volumes. Review subcutaneous injection basics for technique, and always verify batch purity by reading the COA.

Frequently asked questions

Also known as: Semax, ACTH(4-10)-Pro-Gly-Pro, Semax Heptapeptide, MEHFPGP, ACTH 4-10 Analogue, Semax Acetate, N-Acetyl Semax, Семакс